[Skip to Content]
[Skip to Content Landing]
Correction
September 2017

Caution Advised for Readers of Letters Related to Retracted Articles

JAMA Intern Med. 2017;177(9):1400. doi:10.1001/jamainternmed.2017.4594

Two Original Investigations, “The Prevention of Hip Fracture With Risedronate and Ergocalciferol Plus Calcium Supplementation in Elderly Women With Alzheimer Disease: A Randomized Controlled Trial,” and “Risedronate Sodium Therapy for Prevention of Hip Fracture in Men 65 Years or Older After Stroke,” were retracted on June 3, 2016.1,2 A series of Letters3-6 were written to comment on the originally published articles and were published before the Retraction notice. This formal Correction notice is published to alert readers and remind them to not rely on the subsequently retracted articles.

References
1.
Bauchner  H, Redberg  RF.  Notice of retraction: Sato Y, et al. The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trial. Arch Intern Med. 2005;165(15):1737-1742.  JAMA Intern Med. 2016;176(9):1256. doi:10.1001/jamainternmed.2016.3177PubMedGoogle Scholar
2.
Bauchner  H, Redberg  RF.  Notice of retraction: Sato Y, et al. Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Intern Med. 2005;165(15):1743-1748.  JAMA Intern Med. 2016;176(9):1256. doi:10.1001/jamainternmed.2016.3771PubMedGoogle Scholar
3.
Kanna  B, Roffe  E.  Prevention of hip fracture in elderly women with Alzheimer disease.  Arch Intern Med. 2006;166(10):1144-1145. doi:10.1001/archinte.166.10.1144-bPubMedGoogle ScholarCrossref
4.
Sato  Y, Kanoko  T, Satoh  K, Iwamoto  J.  Prevention of hip fracture in elderly women with Alzheimer disease—reply.  Arch Intern Med. 2006;166(10):1145. doi:10.1001/archinte.166.10.1145PubMedGoogle ScholarCrossref
5.
Halbekath  JM, Schenk  S, von Maxen  A, Meyer  G, Mühlhauser  I.  Risedronate for the prevention of hip fractures: concern about validity of trials.  Arch Intern Med. 2007;167(5):513-514. doi:10.1001/archinte.167.5.513-bPubMedGoogle ScholarCrossref
6.
Sato  Y.  Risedronate for the prevention of hip fractures: concern about validity of trials—reply.  Arch Intern Med. 2007;167(5):514-515. doi:10.1001/archinte.167.5.514Google ScholarCrossref
×